98 related articles for article (PubMed ID: 27258566)
1. Gastrointestinal Stromal Tumor: Genotype Frequency and Prognostic Relevance.
Kumari N; Priyaa V; Shukla P; Kumar A; Aggarwal R; Krishnani N
Appl Immunohistochem Mol Morphol; 2018 Mar; 26(3):153-160. PubMed ID: 27258566
[TBL] [Abstract][Full Text] [Related]
2. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
[TBL] [Abstract][Full Text] [Related]
3. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
5. Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour.
Priya V; Kumari N; Krishnani N
Turk Patoloji Derg; 2020; 36(2):116-125. PubMed ID: 31538651
[TBL] [Abstract][Full Text] [Related]
6. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
[No Abstract] [Full Text] [Related]
8. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor.
Quek R; Farid M; Kanjanapan Y; Lim C; Tan IB; Kesavan S; Lim TKH; Oon LL; Goh BK; Chan WH; Teo M; Chung AY; Ong HS; Wong WK; Tan P; Yip D
Asia Pac J Clin Oncol; 2017 Jun; 13(3):115-124. PubMed ID: 27753268
[TBL] [Abstract][Full Text] [Related]
10. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
11. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
12. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of clinicopathologic parameters in gastrointestinal stromal tumor: a study of 156 cases].
Liang YM; Li XH; Lü YY; Lü YL; Zhong M; Pu XL; Li WM
Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):233-8. PubMed ID: 17706113
[TBL] [Abstract][Full Text] [Related]
14. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS
Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613
[TBL] [Abstract][Full Text] [Related]
16. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.
Wozniak A; Rutkowski P; Schöffski P; Ray-Coquard I; Hostein I; Schildhaus HU; Le Cesne A; Bylina E; Limon J; Blay JY; Siedlecki JA; Wardelmann E; Sciot R; Coindre JM; Debiec-Rychter M
Clin Cancer Res; 2014 Dec; 20(23):6105-16. PubMed ID: 25294914
[TBL] [Abstract][Full Text] [Related]
17. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
[TBL] [Abstract][Full Text] [Related]
18. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors.
Braggio E; Braggio Dde A; Small IA; Lopes LF; Valadão M; Gouveia ME; Moreira Ados S; Linhares E; Romano S; Bacchi CE; Renault IZ; Guimarães DP; Ferreira CG
Anticancer Res; 2010 Jun; 30(6):2407-14. PubMed ID: 20651400
[TBL] [Abstract][Full Text] [Related]
20. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
